Hospital
Galencare, INC.
Galencare, INC. was paid $3.56M by Medicaid between Jan 2018 and Dec 2024, across 117 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoGALENCARE, INC.
ST PETERSBURG, FL 33709
ST PETERSBURG, FL 33709
33aNPI1205880945assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.56M
24GClaims263,323
24DCodes billed117
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#95 of 163
Median peer was paid$4.77M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,329 | $152K | |
| 2019 | 65,083 | $561K | |
| 2020 | 48,247 | $464K | |
| 2021 | 50,384 | $739K | |
| 2022 | 42,439 | $963K | |
| 2023 | 21,573 | $455K | |
| 2024incomplete | 10,268 | $223K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 15,207 | 12,850 | $640K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 17,226 | 14,006 | $605K |
| 80053 | Comprehensive metabolic panel | 12% | 21,287 | 15,957 | $443K |
| 70450 | Computed tomography, head or brain; without contrast material | 9.7% | 4,671 | 3,547 | $344K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.6% | 4,315 | 3,160 | $234K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.7% | 1,736 | 1,474 | $203K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.8% | 1,935 | 1,629 | $169K |
| 71045 | Radiologic examination, chest; single view | 3.1% | 8,820 | 7,012 | $112K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 1,617 | 1,466 | $75K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 801 | 722 | $70K |
| G0378 | Hospital observation service, per hour | 1.6% | 3,851 | 2,060 | $57K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 4,418 | 3,122 | $53K |
105 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.3% | 2,020 | $47K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 680 | $47K |
| A9270 | Non-covered item or service | 1.1% | 13,480 | $40K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 1,739 | $40K |
| 87040 | <1% | 2,407 | $34K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 994 | $28K |
| 85027 | <1% | 25,776 | $23K | |
| 81003 | <1% | 10,060 | $20K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,628 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,451 | $18K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,789 | $17K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 721 | $14K |
| 87070 | <1% | 563 | $13K | |
| 87400 | <1% | 1,883 | $13K | |
| 84484 | <1% | 8,409 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,416 | $10K |
| 85610 | <1% | 9,038 | $10K | |
| C1769 | Guide wire | <1% | 161 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,337 | $9K |
| 85730 | <1% | 8,581 | $7K | |
| 83735 | <1% | 9,626 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 142 | $6K |
| 87077 | <1% | 899 | $6K | |
| J3490 | Unclassified drugs | <1% | 250 | $6K |
| 93975 | <1% | 334 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,207 | $5K |
| 73630 | <1% | 245 | $5K | |
| 73610 | <1% | 226 | $5K | |
| 73562 | <1% | 383 | $4K | |
| 73130 | <1% | 186 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 729 | $3K |
| 82803 | <1% | 893 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,489 | $3K |
| 87210 | <1% | 109 | $3K | |
| 73030 | <1% | 233 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,878 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 60 | $3K |
| 83880 | <1% | 2,082 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 541 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,662 | $2K |
| 83690 | <1% | 4,632 | $2K | |
| 36600 | <1% | 811 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 385 | $2K |
| J1815 | Injection, insulin, per 5 units | <1% | 416 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 292 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,329 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,003 | $1K |
| 84703 | <1% | 1,746 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,108 | $1K |
| 84100 | <1% | 1,774 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,444 | $1K |
| 97162 | <1% | 132 | $1K | |
| 82550 | <1% | 1,316 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 262 | $1K |
| 81025 | <1% | 472 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 318 | $1K |
| 84145 | <1% | 305 | $909.88 | |
| 80076 | <1% | 354 | $839.74 | |
| 85379 | <1% | 901 | $804.68 | |
| 73502 | <1% | 83 | $788.03 | |
| 00731 | <1% | 33 | $748.73 | |
| 86900 | <1% | 481 | $654.17 | |
| 97116 | <1% | 22 | $635.75 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 27 | $631.42 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 585 | $625.65 |
| 86901 | <1% | 482 | $612.48 | |
| 73110 | <1% | 45 | $604.84 | |
| 87186 | <1% | 493 | $599.40 | |
| 97161 | <1% | 120 | $596.81 | |
| 72110 | <1% | 151 | $590.20 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 390 | $544.27 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 365 | $520.47 |
| 84702 | <1% | 259 | $487.09 | |
| 80061 | Lipid panel | <1% | 406 | $484.83 |
| 93971 | <1% | 83 | $471.59 | |
| 83605 | <1% | 1,259 | $441.48 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 264 | $317.88 |
| 90714 | <1% | 59 | $317.80 | |
| 86850 | <1% | 258 | $284.83 | |
| J2704 | Injection, propofol, 10 mg | <1% | 335 | $274.62 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 76 | $262.69 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 141 | $223.13 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 473 | $193.65 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 105 | $192.32 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 598 | $186.27 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 283 | $155.10 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 298 | $153.69 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,277 | $151.24 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 133 | $78.14 |
| 97165 | <1% | 123 | $26.31 | |
| 87205 | <1% | 17 | $1.82 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 62 | $0.16 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 116 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 228 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 38 | $0.00 |
| 90715 | 0% | 18 | $0.00 | |
| 00811 | 0% | 24 | $0.00 | |
| 96376 | 0% | 713 | $0.00 | |
| 81001 | 0% | 46 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 16 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 54 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 15 | $0.00 |
| 76830 | Ultrasound, transvaginal | 0% | 14 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 50 | $0.00 |
| 82270 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENRY, CAMILLE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Fort Walton Beach Medical Center, INC. | Ft Walton Beach, FL | $10.30M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.